Bruker Corporation (NASDAQ:BRKR) Stock Has Average Target Price of $58.57 According to Brokerages

Key Points

• Bruker has a “Moderate Buy” consensus among 14 analysts, with an average 12-month price target of $58.57; recommendations include six buys, two strong buys, five holds and one sell.
• Recent analyst views were mixed, with Leerink Partners raising its target to $80 and Goldman Sachs upgrading the stock to strong buy, while Citigroup cut its target to $53 and maintained a hold rating.
• Bruker’s latest quarterly results beat EPS expectations at $0.49 versus $0.38, although revenue of $838.5 million fell short of estimates. Shares opened at $57.92, and the company maintains a $0.20 annualized dividend yielding 0.3%.

Bruker Corporation (NASDAQ:BRKR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the fourteen brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, six have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $58.57.

BRKR has been the subject of a number of analyst reports. Citigroup decreased their target price on shares of Bruker from $60.00 to $53.00 and set a "hold" rating for the company in a research note on Wednesday, August 5th. Leerink Partners increased their target price on Bruker from $60.00 to $80.00 and gave the company an "outperform" rating in a research note on Tuesday, September 29th. The Goldman Sachs Group upgraded shares of Bruker from a "strong sell" rating to a "strong-buy" rating in a research report on Monday, September 21st. TD Cowen reissued a "hold" rating on shares of Bruker in a research report on Wednesday, July 15th. Finally, Stifel Nicolaus set a $50.00 price objective on shares of Bruker in a research report on Wednesday, August 5th.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $57.92 on Friday. Bruker has a 1 year low of $32.37 and a 1 year high of $66.98. The company's 50-day moving average is $58.72 and its 200 day moving average is $52.58. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The stock has a market capitalization of $8.82 billion, a P/E ratio of -82.74, a P/E/G ratio of 1.83 and a beta of 1.22.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.11. The company had revenue of $838.50 million during the quarter, compared to analysts' expectations of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The firm's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, sell-side analysts expect that Bruker will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st were given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date was Monday, September 21st. Bruker's dividend payout ratio (DPR) is presently -28.57%.

Insider Buying and Selling

In other news, VP Mark Munch sold 2,000 shares of the business's stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total value of $105,740.00. Following the transaction, the vice president directly owned 134,806 shares in the company, valued at $7,127,193.22. The trade was a 1.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 27.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bruker

Several hedge funds have recently modified their holdings of the stock. Arizona State Retirement System boosted its position in shares of Bruker by 0.6% during the 2nd quarter. Arizona State Retirement System now owns 29,402 shares of the medical research company's stock valued at $1,769,000 after acquiring an additional 188 shares during the last quarter. IFP Advisors Inc lifted its position in Bruker by 88.6% in the second quarter. IFP Advisors Inc now owns 1,060 shares of the medical research company's stock worth $64,000 after buying an additional 498 shares during the last quarter. State of Michigan Retirement System boosted its stake in Bruker by 1.9% during the first quarter. State of Michigan Retirement System now owns 26,693 shares of the medical research company's stock worth $964,000 after buying an additional 500 shares during the period. Oregon Public Employees Retirement Fund increased its position in Bruker by 2.7% during the first quarter. Oregon Public Employees Retirement Fund now owns 22,767 shares of the medical research company's stock valued at $822,000 after acquiring an additional 600 shares during the last quarter. Finally, Cetera Investment Advisers grew its holdings in Bruker by 4.9% during the 1st quarter. Cetera Investment Advisers now owns 13,184 shares of the medical research company's stock valued at $476,000 after purchasing an additional 612 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, chemicals, biological samples and industrial products. Its customers include academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, environmental laboratories and industrial manufacturers.

The company's portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray instruments, microscopy and surface-analysis platforms, molecular spectroscopy systems, and analytical tools for proteomics, spatial biology, metabolomics and materials research.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.